Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entrada TherapeuticsTRDA +7.28%35 Debt-to-Equity is 0.18 as of Mar. 2026, which is 20% above its 10-year median of 0.15. GuruFocus rates TRDA with a GF Score™ of 35/100 and a GF Value™ of $1.10 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 968 Biotechnology companies, Entrada Therapeutics ranks worse than 51.55% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Entrada Therapeutics's Debt-to-Equity or its related term are showing as below:
TRDA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.15 Max: 0.35
Current: 0.18
During the past 7 years, the highest Debt-to-Equity Ratio of Entrada Therapeutics was 0.35. The lowest was 0.07. And the median was 0.15.
TRDA's Debt-to-Equity is ranked worse than 51.55% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs TRDA: 0.18
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Entrada Therapeutics Debt-to-Equity Related Terms
Entrada Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Entrada Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRDA vs ACIU, TARA, SRZN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Entrada Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics (TRDA) has a Debt-to-Equity of 0.18 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Entrada Therapeutics and its competitors. This is 20% above median its historical median of 0.15. Over the past decade, Entrada Therapeutics' Debt-to-Equity has ranged from 0.07 to 0.35. According to the industry distribution chart, Entrada Therapeutics ranks #499 out of 968 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Entrada Therapeutics' Debt-to-Equity too high?
Entrada Therapeutics' current Debt-to-Equity of 0.18 is 20% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.35. The Biotechnology industry median Debt-to-Equity is 0.16. Entrada Therapeutics' value of 0.18 is 12.5% above this industry median. Based on the distribution chart, Entrada Therapeutics ranks #499 out of 968 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Entrada Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Debt-to-Equity compare to ACIU and TARA?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #499 out of 968 companies for Debt-to-Equity. This places Entrada Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Entrada Therapeutics' value of 0.18 is 12.5% above this benchmark. Historically, Entrada Therapeutics' own Debt-to-Equity has ranged from 0.07 to 0.35 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.16, Entrada Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entrada Therapeutics's current Debt-to-Equity of 0.18 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Entrada Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entrada Therapeutics's current Debt-to-Equity is 0.18, which is 20% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.10, compared to a current price of $7.29 — trading 562.7% above its estimated fair value. The current Debt-to-Equity is 0.18, which is 20% above median its 10-year median of 0.15 and 12.5% above the Biotechnology industry median of 0.16. Entrada Therapeutics' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Debt-to-Equity is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entrada Therapeutics (TRDA) Overvalued in 2026?
Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued.
The current stock price of $7.29 is trading 562.7% above its estimated GF Value™ of $1.10.
GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.
Key valuation signals for TRDA:
Debt-to-Equity: 0.18 (20% above median its 10-year median of 0.15)
GF Value™: $1.10 vs. price of $7.29 (562.7% above fair value)
Industry Position: 12.5% above the Biotechnology median (#499 of 968)
No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
35GF Score
Get the complete analysis for TRDA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRDA has been successfully added to your 
